Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones
  -Event-Driven 2017 Includes MAA Filing for IV Eravacycline in Europe and Top-Line Data Readout from IGNITE4 in cIAI - - Company to Host Conference Call Today, March 8, 2017 at 4:30 p.m. ET - WATERTOWN, Mass. , March 08, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference
WATERTOWN, Mass. , March 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
WATERTOWN, Mass. , March 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth
View HTML
Toggle Summary Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI
WATERTOWN, Mass. , Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company's phase 3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem in
View HTML
Toggle Summary Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline
- Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017 - - Phase 3 IGNITE3 Study in Complicated Urinary Tract Infections to Commence in First Quarter of 2017 - WATERTOWN, Mass. , Dec.
View HTML
Toggle Summary Tetraphase Publishes Phase 3 IGNITE1 Eravacycline Data in JAMA Surgery
WATERTOWN, Mass. , Nov. 17, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the publication of results from IGNITE1, the
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
WATERTOWN, Mass. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Third Quarter 2016 Financial Results and Reviews Recent Progress
WATERTOWN, Mass. , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016
WATERTOWN, Mass. , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced eight data presentations at IDWeek 2016, taking place October 26-30 in New Orleans , LA.  Presentations will include information about the company's phase 3 antibiotic candidate,
View HTML
Toggle Summary Tetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI
Top-line IGNITE4 Data Expected in 4Q 2017 Results to Support NDA Filing for IV Eravacycline in cIAI WATERTOWN, Mass. , Oct. 14, 2016 (GLOBE NEWSWIRE) --   Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE4, the Company's phase 3 clinical trial
View HTML